Horizon BCBS partners with RCCA to improve quality of care for breast cancer patients by evaluating their molecular subtype before administering treatment.
Horizon Blue Cross Blue Shield of New Jersey announced Tuesday that it has joined with Hackensack-based Regional Cancer Care Associates, one of the nation's largest oncology groups, to create an innovative program to deliver specialized care to breast cancer patients. The RCCA physicians, more than 100 at 24 New Jersey locations, will be compensated for the quality rather than the quantity of care their breast cancer patients receive.
The program began Oct. 1 and uses a real-time data platform, developed by the Hackensack-based oncology data firm COTA, Inc., that customizes treatment by categorizing a patient’s cancer by molecular subtype. The COTA platform also supports the effort to move from a fee-for-service to value-based reimbursement system for physicians.
Link to the news on NJBIZ: http://bit.ly/1rg4vS8
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More